LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.
-
Filed today
-
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there - you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings -
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Biocon reported higher quarterly profits and revenue, while also announcing a change in its Chief Technology Officer.
🤖 AI Summary
Biocon's standalone profit for Q2 FY27 increased to Rs. 917 Million from Rs. 709 Million in Q2 FY26.
Revenue from operations reached Rs. 6,305 Million for the quarter ended September 30, 2026.
Dr. Mandar Shrikant Ghatnekar resigned as Chief Technology Officer, effective December 31, 2026.
Mr. Mukesh Rathi appointed as the new Chief Technology Officer, effective January 01, 2027.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Profit for Q2 FY27
917 Million
29.34%
Revenue from operations for Q2 FY27
6,305 Million
8.09%
Total income for Q2 FY27
7,212 Million
0.57%
Basic EPS for Q2 FY27
0.56
1.82%
🏢 How This Affects the Company
📈
Business Impact
The positive trend in revenue from operations may indicate growth in core business activities, reflecting market demand for Biocon's products and services.
💰
Financial Impact
Profit for the period has increased significantly both quarter-on-quarter and year-on-year, contributing positively to the company's standalone financial performance.
⚙️
Operational Impact
The change in Chief Technology Officer could lead to new strategic directions in digital transformation, AI integration, and technology management, given Mr. Mukesh Rathi's extensive experience.
⚠️
Risk Impact
A leadership transition in a critical technology role presents a period of adjustment but Mr. Rathi's background suggests a focus on digital innovation and process excellence.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are indirectly affected by the financial performance, as stronger profits of Rs. 917 Million contribute to overall company value. The management change affects future strategic direction.
🔍
Management Signal
The appointment of Mr. Mukesh Rathi, with extensive experience in digital transformation and AI, signals management's intent to strengthen technological capabilities and innovation.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 results — monitor profit and revenue growth trends.
Management statements regarding Mr. Rathi's strategic technology initiatives.
Company performance in digital transformation and AI-led innovation.
LOW RISKFinancial results show positive growth, and management change is a planned transition with an experienced replacement.
💡 Investor Takeaway
Biocon reported a Q2 FY27 standalone profit of Rs. 917 Million, up from Rs. 709 Million in Q2 FY26, with revenue from operations at Rs. 6,305 Million. The company also announced Mr. Mukesh Rathi as the new CTO, effective January 01, 2027.
⚖️ Strengths & Concerns
✅ Positives
Standalone profit for Q2 FY27 increased to Rs. 917 Million, a 29.34% rise from Rs. 709 Million in Q2 FY26.
Revenue from operations grew to Rs. 6,305 Million in Q2 FY27, up 8.09% from Rs. 5,833 Million in Q2 FY26.
⚠️ Concerns
Other income for Q2 FY27 decreased to Rs. 907 Million from Rs. 1,338 Million in Q2 FY26, a 32.21% decline.
Finance costs for the half-year ended September 30, 2026, were Rs. 392 Million, a 68.23% reduction compared to Rs. 1,234 Million in the previous corresponding period.
❓ Frequently Asked Questions
What was Biocon's standalone net profit in Q2 FY27?
Biocon's standalone profit for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 917 Million.
What was Biocon's revenue from operations in Q2 FY27?
Biocon reported revenue from operations of Rs. 6,305 Million for Q2 FY27, compared to Rs. 5,833 Million in Q2 FY26.
Who is the new Chief Technology Officer appointed at Biocon?
Mr. Mukesh Rathi has been appointed as the Chief Technology Officer (Senior Management Personnel) of Biocon Ltd., effective January 01, 2027.
What was the change in Biocon's Earnings Per Share (Basic) for Q2 FY27?
Biocon's Basic Earnings Per Share for Q2 FY27 was Rs. 0.56, an increase from Rs. 0.55 in Q2 FY26.
Questions based on this BSE filing only. For information purposes.
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again - explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.